This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Zacks Industry Outlook Highlights Philip Morris, Altria Group and 22nd Century
by Zacks Equity Research
Philip Morris, Altria Group and 22nd Century have been highlighted in this Industry Outlook article.
Watch These 3 Tobacco Stocks on Favorable Industry Trends
by Vrishali Bagree
The Zacks Tobacco industry players gain from their pricing power and focus on smoke-free products amid cost inflation and low cigarette volumes. Philip Morris (PM), Altria Group (MO) and 22nd Century Group (XXII) look well-placed.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $44.15, marking a +0.46% move from the previous day.
Is Trending Stock Altria Group, Inc. (MO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Altria (MO) Gains on Pricing Power Amid Low Cigarette Volumes
by Zacks Equity Research
Altria's (MO) Oral Tobacco Products strength and robust pricing power bode well amid soft cigarette volumes. Increased inflation causes consumers to alter their buying patterns.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $45.22, marking a -0.31% move from the previous day.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $45.33, moving +1.68% from the previous trading session.
Altria (MO) Lowers EPS View on Closing NJOY Holdings' Buyout
by Zacks Equity Research
Altria (MO) acquires NJOY Holdings and accordingly updates its adjusted EPS guidance for the full-year 2023.
Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Altria Group, Inc. (MO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Altria (MO). This makes it worthwhile to examine what the stock has in store.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Altria Group, Inc. (MO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Altria (MO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Altria's (MO) Q1 Earnings Lag Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) first-quarter 2023 results benefit from increased pricing, but lower shipment volumes remain a downside.
Altria (MO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of -0.84% and 4.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Factors to Consider Ahead of Medifast's (MED) Q1 Earnings
by Zacks Equity Research
Medifast's (MED) first-quarter performance is likely to reflect the adverse impacts of macroeconomic volatility and increased inflation.
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHD
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx
by Zacks Equity Research
Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.
Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group
by Sheraz Mian
Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).
Factors Setting the Tone of Altria's (MO) Q1 Earnings Release
by Zacks Equity Research
Altria's (MO) first-quarter performance is likely to have witnessed gains from pricing power and oral tobacco product strength amid low cigarette volumes.
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPHD
Factors to Consider Ahead of Mondelez's (MDLZ) Q1 Earnings
by Zacks Equity Research
Mondelez's (MDLZ) first-quarter 2023 earnings will likely reflect gains from strategic buyouts. However, the impacts of global cost inflation and supply chain issues are a concern.
Things to Consider Before Hershey (HSY) Reports Q1 Earnings
by Zacks Equity Research
Hershey's (HSY) first-quarter 2023 earnings will likely reflect gains from strategic pricing actions and prudent buyouts.
Factors to Watch Before Helen of Troy's (HELE) Q4 Earnings
by Zacks Equity Research
Helen of Troy's (HELE) fourth-quarter performance is likely to have witnessed a decline in earnings due to cost headwinds. However, strength in Leadership Brands is likely to have offered respite.